222 related articles for article (PubMed ID: 12402423)
1. [Cytokine therapy for metastatic renal cell carcinoma].
Eto M; Naito S
Gan To Kagaku Ryoho; 2002 Oct; 29(10):1738-44. PubMed ID: 12402423
[TBL] [Abstract][Full Text] [Related]
2. Cytokine therapy for metastatic renal cell carcinoma.
Bukowski RM
Semin Urol Oncol; 2001 May; 19(2):148-54. PubMed ID: 11354535
[TBL] [Abstract][Full Text] [Related]
3. Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma.
Bukowski RM
Semin Oncol; 2000 Apr; 27(2):204-12. PubMed ID: 10768599
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667
[TBL] [Abstract][Full Text] [Related]
5. Cytokine and vaccine therapy of kidney cancer.
Doehn C; Kausch I; Melz S; Behm A; Jocham D
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1097-111. PubMed ID: 15606336
[TBL] [Abstract][Full Text] [Related]
6. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
Parton M; Gore M; Eisen T
J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
8. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma.
Atkins MB; Regan M; McDermott D
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6342S-6S. PubMed ID: 15448028
[TBL] [Abstract][Full Text] [Related]
9. Treatment of metastatic renal cell carcinoma.
Reeves DJ; Liu CY
Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
[TBL] [Abstract][Full Text] [Related]
10. Cytokine therapy: a standard of care for metastatic renal cell carcinoma?
Hutson TE; Quinn DI
Clin Genitourin Cancer; 2005 Dec; 4(3):181-6. PubMed ID: 16425986
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma.
Donskov F
Dan Med Bull; 2007 Nov; 54(4):249-65. PubMed ID: 18208677
[TBL] [Abstract][Full Text] [Related]
12. Advances in immune-based therapies of renal cell carcinoma.
Lam JS; Belldegrun AS; Figlin RA
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1081-96. PubMed ID: 15606335
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
Tourani JM; Pfister C; Tubiana N; Ouldkaci M; Prevot G; Lucas V; Oudard S; Malet M; Cottu P; Ferrero JM; Mayeur D; Rixe O; Sun XS; Bernard O; Andre T; Tournigand C; Muracciole X; Guilhot J;
J Clin Oncol; 2003 Nov; 21(21):3987-94. PubMed ID: 14581421
[TBL] [Abstract][Full Text] [Related]
14. Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer.
Porta C
Expert Rev Anticancer Ther; 2006 Jan; 6(1):141-52. PubMed ID: 16375651
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response.
McDermott DF; Atkins MB
Semin Oncol; 2006 Oct; 33(5):583-7. PubMed ID: 17045087
[TBL] [Abstract][Full Text] [Related]
16. [Interferon-based cytokine therapy for advanced renal cell carcinoma].
Takayama T; Kai F; Sugiyama T; Furuse H; Mugiya S; Ozono S
Hinyokika Kiyo; 2005 Aug; 51(8):499-502. PubMed ID: 16164263
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie.
Ravaud A; Delva R; Gomez F; Chevreau C; Douillard JY; Peny J; Coudert B; Négrier S;
Cancer; 2002 Dec; 95(11):2324-30. PubMed ID: 12436438
[TBL] [Abstract][Full Text] [Related]
18. Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer.
Négrier S; Perol D; Ravaud A; Bay JO; Oudard S; Chabaud S; Fargeot P; Delva R; Deplanque G; Gravis G; Escudier B;
Clin Cancer Res; 2008 Sep; 14(18):5907-12. PubMed ID: 18794104
[TBL] [Abstract][Full Text] [Related]
19. Relation of prenephrectomy CD profiles and serum cytokines to the disease outcome and response to IFN-alpha/IL-2 therapy in renal cell carcinoma patients.
Lauerová L; Dusek L; Spurny V; Simicková M; Rovny A; Rejthar A; Kocák I; Kovarík J
Oncol Rep; 2001; 8(3):685-92. PubMed ID: 11295103
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for metastatic renal cell carcinoma.
Wirth MP
Urol Clin North Am; 1993 May; 20(2):283-95. PubMed ID: 7684167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
